ES2987267T3 - Uso de inhibidores de CCR3 para tratar degeneración macular seca relacionada con la edad - Google Patents

Uso de inhibidores de CCR3 para tratar degeneración macular seca relacionada con la edad Download PDF

Info

Publication number
ES2987267T3
ES2987267T3 ES20174399T ES20174399T ES2987267T3 ES 2987267 T3 ES2987267 T3 ES 2987267T3 ES 20174399 T ES20174399 T ES 20174399T ES 20174399 T ES20174399 T ES 20174399T ES 2987267 T3 ES2987267 T3 ES 2987267T3
Authority
ES
Spain
Prior art keywords
alkyl
eosinophilic
macular degeneration
related macular
chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES20174399T
Other languages
English (en)
Spanish (es)
Inventor
Michael Chadham Nivens
Thierry Bouyssou
Rolf Goeggel
Peter Seither
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkahest Inc
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48040249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2987267(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alkahest Inc filed Critical Alkahest Inc
Application granted granted Critical
Publication of ES2987267T3 publication Critical patent/ES2987267T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Structure Of Transmissions (AREA)
ES20174399T 2012-04-03 2013-04-02 Uso de inhibidores de CCR3 para tratar degeneración macular seca relacionada con la edad Active ES2987267T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12162937 2012-04-03

Publications (1)

Publication Number Publication Date
ES2987267T3 true ES2987267T3 (es) 2024-11-14

Family

ID=48040249

Family Applications (2)

Application Number Title Priority Date Filing Date
ES20174399T Active ES2987267T3 (es) 2012-04-03 2013-04-02 Uso de inhibidores de CCR3 para tratar degeneración macular seca relacionada con la edad
ES13713199T Active ES2811554T3 (es) 2012-04-03 2013-04-02 Uso de inhibidores de CCR3

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES13713199T Active ES2811554T3 (es) 2012-04-03 2013-04-02 Uso de inhibidores de CCR3

Country Status (28)

Country Link
US (5) US20130261153A1 (enrdf_load_stackoverflow)
EP (3) EP4389217A3 (enrdf_load_stackoverflow)
JP (2) JP2015512432A (enrdf_load_stackoverflow)
KR (5) KR20220132012A (enrdf_load_stackoverflow)
CN (2) CN104220073A (enrdf_load_stackoverflow)
AU (1) AU2013245027B2 (enrdf_load_stackoverflow)
BR (1) BR112014023795B1 (enrdf_load_stackoverflow)
CA (1) CA2869269C (enrdf_load_stackoverflow)
CL (1) CL2014002523A1 (enrdf_load_stackoverflow)
CY (1) CY1123222T1 (enrdf_load_stackoverflow)
DK (1) DK2833884T3 (enrdf_load_stackoverflow)
EA (1) EA032263B1 (enrdf_load_stackoverflow)
ES (2) ES2987267T3 (enrdf_load_stackoverflow)
HR (1) HRP20201165T1 (enrdf_load_stackoverflow)
HU (1) HUE051648T2 (enrdf_load_stackoverflow)
IL (1) IL234262A (enrdf_load_stackoverflow)
IN (1) IN2014DN06989A (enrdf_load_stackoverflow)
LT (1) LT2833884T (enrdf_load_stackoverflow)
MX (1) MX2014011786A (enrdf_load_stackoverflow)
NZ (1) NZ628882A (enrdf_load_stackoverflow)
PH (1) PH12014502239A1 (enrdf_load_stackoverflow)
PL (1) PL2833884T3 (enrdf_load_stackoverflow)
PT (1) PT2833884T (enrdf_load_stackoverflow)
RS (1) RS60665B1 (enrdf_load_stackoverflow)
SI (1) SI2833884T1 (enrdf_load_stackoverflow)
SM (1) SMT202000499T1 (enrdf_load_stackoverflow)
WO (1) WO2013149986A1 (enrdf_load_stackoverflow)
ZA (1) ZA201406082B (enrdf_load_stackoverflow)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
AR090566A1 (es) 2012-04-02 2014-11-19 Boehringer Ingelheim Int Proceso para la produccion de inhibidores de crr
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2018097209A1 (ja) 2016-11-24 2018-05-31 キリシマ精工株式会社 歯列矯正具、および歯列矯正具の取付方法
JP2020513005A (ja) 2017-04-05 2020-04-30 アルカヘスト,インコーポレイテッド Ccr3阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物
EP4245295B1 (en) * 2017-04-05 2025-08-06 Alkahest, Inc. Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors
US20190111042A1 (en) * 2017-10-13 2019-04-18 Alkahest, Inc. Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR-Inhibitors
MY198220A (en) 2018-05-15 2023-08-14 Alkahest Inc Treatment Of Aging-Associated Disease With Modulators Of Leukotriene A4 Hydrolase
SG11202102105VA (en) * 2018-09-26 2021-04-29 Alkahest Inc Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
EP4164643A4 (en) * 2020-06-11 2024-07-03 Alkahest, Inc. METHODS OF IMPROVING THE OUTCOME OF RETINAL-ASSOCIATED DISEASE USING CCR3 INHIBITORS
JP2024542963A (ja) 2021-11-01 2024-11-19 アルカヘスト,インコーポレイテッド 加齢関連疾患の予防及び治療のためのロイコトリエンa4加水分解酵素(lta4h)のベンゾジオキサン調節剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339087B1 (en) * 1997-08-18 2002-01-15 Syntex (U.S.A.) Llc Cyclic amine derivatives-CCR-3 receptor antagonists
JP5198704B2 (ja) * 2000-03-03 2013-05-15 メディミューン リミティド エオタキシンに対するヒト抗体及びそれらの使用
US20020151064A1 (en) * 2001-02-07 2002-10-17 Children's Hospital Medical Center Regulation of CCR3 expression
WO2006083390A2 (en) * 2004-12-07 2006-08-10 Children's Hospital Medical Center Eotaxin-3 in eosinophilic esophagitis
US8008092B2 (en) * 2007-10-09 2011-08-30 University Of Kentucky Research Foundation CCR3 inhibition for ocular angiogenesis and macular degeneration
WO2010069979A1 (en) * 2008-12-16 2010-06-24 Nycomed Gmbh Pyran derivatives as ccr3 modulators
EP2236520A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Stabilizing composition for immobilized biomolecules
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
US8778616B2 (en) * 2009-05-26 2014-07-15 University Of Kentucky Research Foundation Method of using CCR3 binding agents to detect choroidal neovascularization
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2020115836A1 (ja) * 2018-12-05 2020-06-11 東浜工業株式会社 ブロワー装置

Also Published As

Publication number Publication date
HRP20201165T1 (hr) 2020-12-11
EP2833884A1 (en) 2015-02-11
WO2013149986A1 (en) 2013-10-10
US20150099783A1 (en) 2015-04-09
EA032263B1 (ru) 2019-05-31
ES2811554T3 (es) 2021-03-12
CA2869269A1 (en) 2013-10-10
KR20140144200A (ko) 2014-12-18
CA2869269C (en) 2020-06-30
CL2014002523A1 (es) 2015-01-23
AU2013245027A1 (en) 2014-09-11
EA201401083A1 (ru) 2015-03-31
US20160081998A1 (en) 2016-03-24
US20130261153A1 (en) 2013-10-03
SI2833884T1 (sl) 2020-10-30
AU2013245027B2 (en) 2017-10-12
BR112014023795A2 (enrdf_load_stackoverflow) 2017-06-20
IL234262A (en) 2017-10-31
LT2833884T (lt) 2020-09-10
PL2833884T3 (pl) 2020-11-02
KR20220132012A (ko) 2022-09-29
IN2014DN06989A (enrdf_load_stackoverflow) 2015-04-10
JP2018080183A (ja) 2018-05-24
EP3763369A1 (en) 2021-01-13
BR112014023795B1 (pt) 2021-09-08
JP2015512432A (ja) 2015-04-27
NZ628882A (en) 2016-05-27
CN104220073A (zh) 2014-12-17
CY1123222T1 (el) 2021-10-29
PT2833884T (pt) 2020-08-26
PH12014502239A1 (en) 2014-12-15
EP4389217A3 (en) 2024-08-28
KR20210063481A (ko) 2021-06-01
EP2833884B1 (en) 2020-05-20
US20170319567A1 (en) 2017-11-09
DK2833884T3 (da) 2020-08-10
KR20250133980A (ko) 2025-09-09
SMT202000499T1 (it) 2020-11-10
MX2014011786A (es) 2014-12-05
EP3763369B1 (en) 2024-02-28
HUE051648T2 (hu) 2021-03-29
RS60665B1 (sr) 2020-09-30
BR112014023795A8 (pt) 2017-10-10
CN110384699A (zh) 2019-10-29
ZA201406082B (en) 2019-01-30
EP4389217A2 (en) 2024-06-26
KR20200044988A (ko) 2020-04-29
US20200375971A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
ES2987267T3 (es) Uso de inhibidores de CCR3 para tratar degeneración macular seca relacionada con la edad
US11612596B2 (en) Pharmaceutical formulations comprising CCR3 antagonists
ES2370751T3 (es) Agente profiláctico o terapéutico para la degeneración macular asociada a la edad.
RU2406499C2 (ru) Профилактическое или терапевтическое средство для лечения кератоконъюнктивитных нарушений
JPS63185927A (ja) 薬物中毒治療のための医薬
ES2950453T3 (es) Compuestos y composiciones farmacéuticas para su uso en el tratamiento de enfermedades asociadas a la retina utilizando inhibidores de la CCR3
HK40015701A (en) Use of ccr3-inhibitors
CA2542620A1 (en) Method of treating snoring and other obstructive breathing disorders
JP2010111667A (ja) フェキソフェナジン又はエバスチンを含有する鎮咳及び/又は去痰のための医薬組成物
WO2016006621A1 (ja) Pgd2拮抗剤を含有するアレルギー性疾患に伴う症状の治療用医薬
WO2007066678A1 (ja) 角結膜障害治療剤
JP2010111666A (ja) セチリジンを含有する鎮咳及び/又は去痰のための医薬組成物